No abstract available.
Lung Injury* ; Lung* ; Paraquat*

No abstract available.
Hemoptysis*

No abstract available.
Humans ; Lung Neoplasms* ; Lung*

No abstract available.
Anemia* ; Gastrectomy* ; Vitamin B 12 Deficiency* ; Vitamin B 12* ; Vitamins*

Six cases of nasal septum perforation were found among welders during periodic physical checkup in 1997. Considering the size, shape and margin, the perforations were assumed to have been occurred several years before of which the diameter were 8~15 mm. To investigate the cause of perforation, we reviewed the past history of preemployment, the results of annual working environment survey and the material safety data sheets of welding rods and steels with which they have dealt, and analyzed the concentration of several metals of welding fume and the concentration of blood and urinary chromium. In the result, we presupposed that the nasal septum perforations of welders were due to chronic exposure to low level hexavalent chromium and/or nickel, and report these cases with literatures review.
Chromium ; Material Safety Data Sheets ; Metals ; Nasal Septal Perforation* ; Nasal Septum* ; Nickel ; Steel ; Welding

BACKGROUND: Several predictor of successful outcome after percutaneous mitral valvuloplasty(PMV) have been identified but the results were controversial. We analyzes the clinical and echocardiographic predictors of successful outcome after PMV. METHOD: We studied 214 patients(167 women and 47 men) undergoing PMV from October 1991 to December 1995. Echocardiographic evaluation was performed before and after PMV. RESULT: The study population had mean age of 41+/-11years, and the total echocardiographic score was 7.5+/-1.5. PMV using Inoue balloon and double balloon technique were performed in 113cases and 101 cases respectively. The successful outcome from PMV(defindedas mitral valve area > or =1.5cm2 and increase in valve area >+25% and less than grade 3 mitral regurgitation(MR)) was achieved in 178 cases(83.2%). The mean mitral valve area was increased from 0.90+/-0.21cm2 to 1.82+/-0.34cm2(p<0.01). The successful outcome group had good echocardiographic score(7.3+/-1.4 vs. 8.8+/-1.4, p<0.01) and larger valve area before procedure(0.92+/-0.21cm2 vs. o.75+/-0.17cm2, p<0.01) than suboptimal result group. The patients with total echocardiographic score <=8 had more increment in valve area after PMV(0.97+/-0.21cm2) than those with total echocardiographic score >8(0.83+/-0.22cm2, p<0.01). Significant MR(>=grade 3 MR) after PMV was developed in 10 cases(4.7%). In patients with significant MR afterPMV, echocardiographic calcification score were high(2.3+/-0.8 vs. 1.7+/-0.7, p<0.01) and mitral valve area before PMV were smaller(0.82+/-0.10cm2 vs. 0.90+/-0.22cm2, p<0.05) than in those without significant MR. CONCLUSIONS: The predictors of successful outcome after PMV are large mitral valve area and good echocardiographic score. The predictors of significant MR is severe calcified mitral valveand small mitral valve area before PMV.
Echocardiography ; Female ; Humans ; Mitral Valve

No abstract available.
Echinococcosis, Hepatic*

OBJECTIVE: This study was carried out to compare the clinical outcome of elective single cleavage-embryo transfer (eSCET) to that of elective single blastocyst-embryo transfer (eSBET) in human IVF-ET. METHODS: This study was a retrospective study which analyzed for 614 women who visited the Daegu Maria Clinic from August 2008 to December 2009. All were under 37 years old and had more than 8 mm of endometrial thickness on the day of hCG administration and at least one good quality embryo on day 3. The eSCETs were performed on day 3 (n=450) and the eSBETs were conducted on day 5 (n=164). RESULTS: The numbers of retrieved oocytes, fertilized oocytes, and day 3 good quality embryos were significantly lower in the eSCET group (12.1+/-6.0, 8.2+/-4.6, and 4.2+/-3.1, respectively) compared to the eSBET group (16.7+/-7.2, 12.1+/-5.0, and 8.5+/-4.5, respectively; p<0.001). However, the clinical pregnancy, implantation, on-going pregnancy, and live birth rates of the eSCET group (46.7, 46.9, 40.0, and 36.7%, respectively) were not statistically different from those of the eSBET group (51.2, 51.8, 45.1, and 43.9%, respectively; p=0.318, 0.278, 0.254, and 0.103, respectively). CONCLUSION: These results suggested that elective single embryo transfer should be performed regardless of the developmental stage to women less than 37 years old who had more than 8 mm of endometrial thickness on the hCG administration day and at least one good quality embryo on day 3 in order to reduce the twin pregnancy rate without reducing the whole pregnancy rate.
Embryonic Structures ; Female ; Humans ; Live Birth ; Oocytes ; Pregnancy ; Pregnancy Rate ; Pregnancy, Twin ; Retrospective Studies ; Single Embryo Transfer ; Twins

OBJECTIVE: This study was carried out to compare the clinical outcome of elective single cleavage-embryo transfer (eSCET) to that of elective single blastocyst-embryo transfer (eSBET) in human IVF-ET. METHODS: This study was a retrospective study which analyzed for 614 women who visited the Daegu Maria Clinic from August 2008 to December 2009. All were under 37 years old and had more than 8 mm of endometrial thickness on the day of hCG administration and at least one good quality embryo on day 3. The eSCETs were performed on day 3 (n=450) and the eSBETs were conducted on day 5 (n=164). RESULTS: The numbers of retrieved oocytes, fertilized oocytes, and day 3 good quality embryos were significantly lower in the eSCET group (12.1+/-6.0, 8.2+/-4.6, and 4.2+/-3.1, respectively) compared to the eSBET group (16.7+/-7.2, 12.1+/-5.0, and 8.5+/-4.5, respectively; p<0.001). However, the clinical pregnancy, implantation, on-going pregnancy, and live birth rates of the eSCET group (46.7, 46.9, 40.0, and 36.7%, respectively) were not statistically different from those of the eSBET group (51.2, 51.8, 45.1, and 43.9%, respectively; p=0.318, 0.278, 0.254, and 0.103, respectively). CONCLUSION: These results suggested that elective single embryo transfer should be performed regardless of the developmental stage to women less than 37 years old who had more than 8 mm of endometrial thickness on the hCG administration day and at least one good quality embryo on day 3 in order to reduce the twin pregnancy rate without reducing the whole pregnancy rate.
Embryonic Structures ; Female ; Humans ; Live Birth ; Oocytes ; Pregnancy ; Pregnancy Rate ; Pregnancy, Twin ; Retrospective Studies ; Single Embryo Transfer ; Twins

PURPOSE: Many reports have shown that the efficacy of intravesical therapy for bladder cancer is, in part, limited by the poor penetration of drugs into the urothelium. The present study evaluated the effect of glyceryl monooleate (GMO) on the delivery and penetration of paclitaxel into the bladder of rabbits, when given as an intravesical dose. MATERIALS AND METHODS: The urine, plasma, and tissue pharmacokinetics were determined in rabbits treated for 120min with paclitaxel (500g/20ml) by an intravesical instillation. Two formulation of GMO/paclitaxel were evaluated, according to the proportion of water, 15% and 30%, with Taxol was used as a control. The animals were observed for clinical signs of toxicity, and necropsy performed. RESULTS: At 120min post-instillation, the bladders were emptied and excised. The urine paclitaxel concentrations were decreased by 39.6 and 41.2% in the two experimental groups, and by 25.2% in the control group. The paclitaxel concentrations in the urothelium were 53 and 56% of the urine concentration in the two experimental groups, respectively, but by only 11% in the control group. The concentration then declined exponentially in the underlying capillary perfused tissues, reaching equilibrium at a depth of 1,400-1,700um. The plasma concentrations were extremely low compared with those in the urine and bladder tissues, and were not associated with clinical toxicity. CONCLUSIONS: These results indicate that GMO improves the delivery of paclitaxel and increases the concentration in the bladder tissue. These results suggest that the intravesical delivery of GMO/paclitaxel/water provide a significant bladder tissue targeting advantage, and that paclitaxel represents a viable candidate drug for intravesical bladder cancer therapy.
Administration, Intravesical* ; Animals ; Capillaries ; Drug Delivery Systems* ; Paclitaxel* ; Pharmacokinetics ; Plasma ; Rabbits* ; Urinary Bladder ; Urinary Bladder Neoplasms ; Urothelium ; Water